Funding for this research was provided by:
Medical Research Council (Confidence in Concept)
Text and Data Mining valid from 2019-04-11
Received: 17 December 2018
Accepted: 20 March 2019
First Online: 11 April 2019
Ethics approval and consent to participate
: For metastatic breast cancer patient samples fully informed written consent was obtained. Ethical approval for the Division of Cancer Sciences, Manchester, United Kingdom was also obtained: COREC# 05/ Q1403/25 and 05/Q1403/159.For solid mastectomy samples fully informed consent was obtained by the Northern Ireland Biobank (NIB14–0117).All animal experiments were carried out in accordance with the Animal (Scientific Procedures) Act 1986 and conformed to the current United Kingdom Co-ordinating Committee on Cancer Research guidelines. Animal studies were conducted under the project license PPL 2678 and all researchers also had their personal licenses approved by the Department of Health, Social Services and Public Safety Health Protection in the UK. All animal experiments were carried out in accordance with the Basel Declaration.None of the cell lines required ethical approval for use.
: Not applicable.
: TR has ownership interest as a co-inventor on the patent describing FKBPL’s use in cancer. Almac helped fund the work and provided peptides.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.